PCL (Poly‑ε‑Caprolactone)Polycaprolactone
PCL is suitable for R&D of biomedicine, regenerative materials and cosmetic sustained-release carriers. Indicate intended use and parameter requirements upon inquiry. Xi'an Wanlv provides specification discussion, documents and sample support.
Overview
What is Polycaprolactone?PCL (poly‑ε‑caprolactone) microspheres are aliphatic biodegradable polyester microspheres synthesized via ring‑opening polymerization of caprolactone monomers. It appears as fine white spherical powder. The material exhibits biocompatibility with customizable molecular weight and particle size, featuring narrow particle‑size distribution. It undergoes gradual hydrolytic degradation under physiological conditions and is ultimately metabolized into carbon dioxide and water. It is intended for R&D of Class‑III medical devices including dermal filler products, drug‑delivery carriers and tissue‑engineering materials. It may also be adopted for certain topical formulation development. If used in cosmetic products, customers shall independently complete new raw‑material filing and assessment. Important Notice: This is an upstream powder raw material without medical device registration certificate and must not be injected into human body directly. Downstream injectable finished products shall implement full aseptic manufacturing processes and complete medical‑device registration submission.
Key Parameters
Applications
Medical Device R&D Directions
1. Soft‑tissue filler material R&D: Used as degradable microsphere filler for finished aesthetic dermal filler formulation development. PCL features a long degradation cycle to deliver long‑term mechanical support. The raw material cannot be directly injected into human body; downstream finished products must obtain Class‑III medical device registration. 2. Sustained‑release microsphere drug carrier: Encapsulates peptides and small‑molecule drugs for slow in‑vivo release and prolonged drug action; applied in R&D of subcutaneous and local drug‑delivery formulations. 3. Tissue‑engineering scaffold: Compound with other polymers to fabricate porous scaffolds for research on cartilage and subcutaneous tissue repair. 4. Orthopedic repair consumable R&D: Composite with hydroxyapatite to prepare bone‑repair composite scaffolds for laboratory studies of bone defects.
Pharmaceutical Field
1. Long‑acting sustained‑release formulation carrier, enabling drug release over weeks to months. 2. Base material for degradable implantable drug‑delivery systems. 3. Laboratory research for research‑grade drug‑delivery systems.
Topical Formulation R&D
Topical sustained‑release formulations: Skin‑applied systems loaded with active ingredients for slow‑release performance. For cosmetic applications, customers shall independently complete new cosmetic raw‑material filing and assessment.
Research & Experimental Applications
1. In‑vivo degradation and biocompatibility evaluation tests on animal models. 2. Modification research for polymer composite materials. 3. Powder raw material for 3D‑printable degradable polymer consumables.
Product FAQ
What are PCL Microspheres?
PCL (Polycaprolactone) microspheres are medical‑grade degradable polyester polymer microspheres with highly spherical morphology and favorable biocompatibility. Full biological evaluation shall be completed for downstream finished products. This material can be developed as scaffold base material to induce neocollagenesis. Downstream applications cover Class‑III medical device R&D for regenerative filling, drug sustained‑release and tissue engineering. The material undergoes hydrolytic degradation in‑vivo, and its degradation end‑products are metabolized into carbon dioxide and water, with theoretically no residual polymer matrix.
What are the Key Differences Between PCL and PLLA Microspheres?
PCL microspheres feature smooth particle surfaces, longer degradation cycles and fewer acidic by‑products upon degradation. When compounded with CMC gel carrier for downstream formulation, finished products deliver immediate volumetric filling effect. PLLA mostly presents irregular particle morphology with no immediate filling effect; hydration and standing are required prior to formulation compounding. Material properties differ between the two. Final clinical performance is affected by multiple factors including formulation, injection technique and individual patient variation.
What is the Complete Selection Workflow for PCL Microspheres?
① Define application scenarios: Distinguish aesthetic filling, drug sustained‑release and tissue‑engineering use cases, confirm target medical‑device end‑use. ② Confirm specifications: Lock target molecular weight, D50 particle size, span, and match sterilization method. ③ Gather documentation: Obtain COA, impurity test reports, endotoxin data, residual‑solvent results and registration‑supporting documents for suitability assessment.
Does receipt of documents guarantee full project compatibility?
All parameters, lead‑time, pricing and customization capacity are subject to written confirmation upon formal inquiry. You may contact our business team to obtain samples, COA and registration‑supporting documents for formulation and registration assessment.